International Stem Cell CORP
ISCO · OTCMCIK 1355790fmd_1HH5402NNXEBHRNSNQJM507SPJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2006 to Jun 30, 2026, 69 periods
Loading
Latest annual · FY2025
Millions- Free cash flow
- (0)
Latest quarter · Q2 FY2026
Millions- Total revenues
- 3
- Gross profit
- 1
- Operating income
- (0)
- Net income
- (0)
- Free cash flow
- 0
International Stem Cell CORP (ISCO) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $9.1 million | $9.1 million | +0.2% | 10-K 2026-03-30 · proof |
| Gross profit | $5.1 million | $5.3 million | -4.8% | 10-K 2026-03-30 · proof |
| Operating income | -$267,000 | -$68,000 | 10-K 2026-03-30 · proof | |
| Net income | -$418,000 | -$209,000 | 10-K 2026-03-30 · proof | |
| Cash from operating activities | $8,000 | $13,000 | -38.5% | 10-K 2026-03-30 · proof |
| Free cash flow | -$35,000 | -$153,000 | 10-K 2026-03-30 · proof | |
| Total assets | $4.8 million | $5.2 million | -6.8% | 10-K 2026-03-30 · proof |
| Total liabilities | $4.6 million | $4.8 million | -4.7% | 10-K 2026-03-30 · proof |
| Cash and cash equivalents | $993,000 | $1.2 million | -19.3% | 10-K 2026-03-30 · proof |
- What was International Stem Cell CORP (ISCO)'s revenue in fiscal 2025?
- International Stem Cell CORP (ISCO) reported revenue of $9.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $9.1 million the year before (+0.2%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was International Stem Cell CORP (ISCO)'s gross profit in fiscal 2025?
- International Stem Cell CORP (ISCO) reported gross profit of $5.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $5.3 million the year before (-4.8%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was International Stem Cell CORP (ISCO)'s operating income in fiscal 2025?
- International Stem Cell CORP (ISCO) reported operating income of -$267,000 for fiscal 2025 (the year ended Dec 31, 2025), against -$68,000 the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was International Stem Cell CORP (ISCO)'s net income in fiscal 2025?
- International Stem Cell CORP (ISCO) reported net income of -$418,000 for fiscal 2025 (the year ended Dec 31, 2025), against -$209,000 the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was International Stem Cell CORP (ISCO)'s cash from operating activities in fiscal 2025?
- International Stem Cell CORP (ISCO) reported cash from operating activities of $8,000 for fiscal 2025 (the year ended Dec 31, 2025), against $13,000 the year before (-38.5%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What was International Stem Cell CORP (ISCO)'s free cash flow in fiscal 2025?
- International Stem Cell CORP (ISCO) reported free cash flow of -$35,000 for fiscal 2025 (the year ended Dec 31, 2025), against -$153,000 the year before. Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What are International Stem Cell CORP (ISCO)'s total assets?
- As of Dec 31, 2025, International Stem Cell CORP (ISCO) reported total assets of $4.8 million, against $5.2 million a year earlier (-6.8%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What are International Stem Cell CORP (ISCO)'s total liabilities?
- As of Dec 31, 2025, International Stem Cell CORP (ISCO) reported total liabilities of $4.6 million, against $4.8 million a year earlier (-4.7%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
- What are International Stem Cell CORP (ISCO)'s cash and cash equivalents?
- As of Dec 31, 2025, International Stem Cell CORP (ISCO) reported cash and cash equivalents of $993,000, against $1.2 million a year earlier (-19.3%). Source: the 10-K filed with the SEC on Mar 30, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ISCO&period_type=annual&limit=5"Information only, not investment advice.